Browsing
     by title


0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

or enter first few letters:   
OK
Full Text
Peer Reviewed
See detailOsteoblasts from the sclerotic subchondral bone downregulate aggrecan but upregulate metalloproteinases expression by chondrocytes. This effect is mimicked by interleukin-6, -1 beta and oncostatin M pre-treated non-sclerotic osteoblasts
Sanchez, Christelle ULg; Deberg, Michelle ULg; Piccardi, Nathalie et al

in Osteoarthritis and Cartilage (2005), 13(11), 979-987

OBJECTIVE: To determine the effects of osteoarthritic (OA) subchondral osteoblasts on the metabolism of human OA chondrocytes in alginate beads. METHODS: Human chondrocytes were isolated from OA cartilage ... [more ▼]

OBJECTIVE: To determine the effects of osteoarthritic (OA) subchondral osteoblasts on the metabolism of human OA chondrocytes in alginate beads. METHODS: Human chondrocytes were isolated from OA cartilage and cultured in alginate beads for 4 days in the absence or in the presence of osteoblasts isolated from non-sclerotic (N) or sclerotic (SC) zones of human OA subchondral bone in monolayer (co-culture system). Before co-culture, osteoblasts were incubated for 72 h with or without 1.7ng/ml interleukin (IL)-1beta, 100 ng/ml IL-6 with its soluble receptor (50 ng/ml) or 10 ng/ml oncostatin M (OSM). Aggrecan (AGG) and matrix metalloproteases (MMP)-3 and -13 mRNA levels in chondrocytes were quantified by real-time polymerase chain reaction. AGG production was assayed by a specific enzyme amplified sensitivity immunoassay. RESULTS: SC, but not N, osteoblasts induced a significant inhibition of AGG production and AGG gene expression by human OA chondrocytes in alginate beads, and significantly increased MMP-3 and MMP-13 gene expression by chondrocytes. When they were pre-incubated with IL-1beta, IL-6 or OSM, N osteoblasts inhibited AGG synthesis and increased MMP-3 and -13 gene expression by chondrocytes in alginate beads in a same order of magnitude as SC osteoblasts. CONCLUSIONS: These results demonstrate that SC OA subchondral osteoblasts could contribute to cartilage degradation by stimulating chondrocytes to produce more MMP and also by inhibiting AGG synthesis. [less ▲]

Detailed reference viewed: 63 (7 ULg)
Full Text
Peer Reviewed
See detailOsteochondosis in foals
Sandersen, Charlotte ULg; Vander Heyden, Laurent ULg; Detilleux, Johann ULg et al

in Veterinary Record : Journal of the British Veterinary Association (2013), 127(17), 456-467

Detailed reference viewed: 5 (0 ULg)
Full Text
Peer Reviewed
See detailOsteochondral plate angiogenesis: A new treatment target in osteoarthritis.
Pesesse, Laurence ULg; Sanchez, Christelle ULg; Henrotin, Yves ULg

in Joint Bone Spine (2011), 78

Healthy adult joint cartilage contains neither blood vessels nor nerves. Osteoarthritic cartilage, in contrast, may be invaded by blood vessels from the subchondral bone. The mechanisms underlying ... [more ▼]

Healthy adult joint cartilage contains neither blood vessels nor nerves. Osteoarthritic cartilage, in contrast, may be invaded by blood vessels from the subchondral bone. The mechanisms underlying cartilage angiogenesis in osteoarthritis are unclear but may involve hypertrophic chondrocyte differentiation. Active research is under way to identify the factors involved in cartilage angiogenesis. Here, we discuss the pathophysiological mechanisms of osteoarthritic cartilage angiogenesis based on evidence from a systematic literature review of articles retrieved via PubMed and ISI Web of Knowledge. Our conclusions suggest new research perspectives and treatment options. [less ▲]

Detailed reference viewed: 37 (7 ULg)
Full Text
Peer Reviewed
See detailOsteochondrosis lesion of the lombo-sacral joint in a mastiff
Snaps, Frédéric ULg; Heimann, M.; Saunders, J. et al

in Veterinary Record : Journal of the British Veterinary Association (1998), 143(17), 476-477

Detailed reference viewed: 18 (2 ULg)
Full Text
Peer Reviewed
See detailOsteocyte-derived insulin-like growth factor I is essential for determining bone mechanosensitivity
Lau, K.-H. William; Baylink, David J.; Zhou, Xiao-Dong et al

in American Journal of Physiology - Endocrinology and Metabolism (2013), 305(2), 271-281

This study sought to determine whether deficient Igf1 expression in osteocytes would affect loading-induced osteogenic response. Tibias of osteocyte Igf1 conditional knockout (KO) mice (generated by ... [more ▼]

This study sought to determine whether deficient Igf1 expression in osteocytes would affect loading-induced osteogenic response. Tibias of osteocyte Igf1 conditional knockout (KO) mice (generated by crossbreeding Igf1 floxed mice with Dmp1-Cre transgenic mice) and wild-type (WT) littermates were subjected to four-point bending for 2 wk. Microcomputed tomography confirmed that the size of tibias of conditional mutants was smaller. Loading with an equivalent loading strain increased periosteal woven bone and endosteal lamellar bone formation in WT mice but not in conditional KO mice. Consistent with the lack of an osteogenic response, the loading failed to upregulate expression of early mechanoresponsive genes (Igf1, Cox-2, c-fos) or osteogenic genes (Cbfa-1, and osteocalcin) in conditional KO bones. The lack of osteogenic response was not due to reduced osteocyte density or insufficient loading strain. Deficient osteocyte Igf1 expression reduced the loading-induced upregulation of expression of canonical Wnt signaling genes (Wnt10b, Lrp5, Dkk1, sFrp2). The loading also reduced (by 40%) Sost expression in WT mice, but the loading not only did not reduce but upregulated (similar to 1.5-fold) Sost expression in conditional KO mice. Conditional disruption of Igf1 in osteocytes also abolished the loading-induced increase in the bone beta-catenin protein level. These findings suggest an impaired response in the loading-induced upregulation of the Wnt signaling in conditional KO mice. In summary, conditional disruption of Igf1 in osteocytes abolished the loading-induced activation of the Wnt signaling and the corresponding osteogenic response. In conclusion, osteocyte-derived IGF-I plays a key determining role in bone mechanosensitivity. [less ▲]

Detailed reference viewed: 11 (1 ULg)
Full Text
Peer Reviewed
See detailL'osteodensitometrie dans le depistage de l'osteoporose: le paradoxe Belge
Neuprez, A.; Gillet, Philippe ULg; Collette, C. et al

in Revue Médicale de Liège (2006), 61(4), 249-55

Osteoporosis is considered as a major Public Health issue, in most developed countries. Bone mineral density assessment is the single best predictor of the future fracture risk for an individual. Belgium ... [more ▼]

Osteoporosis is considered as a major Public Health issue, in most developed countries. Bone mineral density assessment is the single best predictor of the future fracture risk for an individual. Belgium has the highest number of bone densitometers, per million habitants, in Europe. However, densitometry is not yet reimbursed in Belgium. This situation is rather paradoxical since the demonstration of a prevalent vertebral fracture or of a low bone mineral density is requested to obtain the reimbursement of drugs to be used for the management of osteoporosis. Hopefully, Belgium will soon be online with the requirement s of the European Commission, suggesting to make bone densitometry accessible, through reimbursement. [less ▲]

Detailed reference viewed: 123 (7 ULg)
Full Text
See detailOsteogenesis imperfecta
Kaux, Jean-François ULg

Conference (2008, January 25)

Detailed reference viewed: 60 (26 ULg)
See detailOstéologie et myologie de Tilapia guineensis
Vandewalle, Pierre ULg

Book (1972)

Detailed reference viewed: 18 (2 ULg)
Full Text
Peer Reviewed
See detailL’ostéomalacie : étiologie, clinique, physiopathologie et thérapeutique
Reginster, Jean-Yves ULg

in Le Monde Médical de la Femme (1996), 330(23), 18-21

Detailed reference viewed: 99 (3 ULg)
Full Text
Peer Reviewed
See detailOstéomalacie hypophosphatémique hyperphosphaturique avec hypersécrétion de FGF-23
COLSON, Laurent ULg; Vander Rest, Catherine; Reginster, Jean-Yves ULg et al

in Lettre du Rhumatologue (La) (2012), 387

Detailed reference viewed: 105 (35 ULg)
Full Text
Peer Reviewed
See detailL'ostéomalacie: étiologie, clinique, physiopathologie et thérapeutiques
Reginster, Jean-Yves ULg; WAGEMANS, Martine ULg; Delvaux, T et al

in Revue Médicale de Liège (1986), 61

Detailed reference viewed: 17 (1 ULg)
Full Text
Peer Reviewed
See detailOsteonecrosis in inflammatory bowel diseases: a review of the literature
Hauzeur, Jean-Philippe ULg; Malaise, Michel ULg; Gangji, V.

in Acta Gastro-Enterologica Belgica (2009), 72(3), 327-334

INTRODUCTION: Osteonecrosis (ON) of the femoral head can lead to femoral head collapse, necessitating total hip replacement. Reports of patients suffering from both ON and Inflammatory Bowel Diseases (IBD ... [more ▼]

INTRODUCTION: Osteonecrosis (ON) of the femoral head can lead to femoral head collapse, necessitating total hip replacement. Reports of patients suffering from both ON and Inflammatory Bowel Diseases (IBD) have prompted us to evaluate the relationship between ON and IBD, especially Crohn's disease and ulcerative colitis. METHODS: A review of the data from three new cases, along with data from all the published cases of patients presenting ON and IBD found through a systematic search of the Pub Med database. RESULTS: We encountered some diagnostic problems: The ON diagnosis could not be confirmed in some patients who did not meet the ON diagnostic criteria. Reviewed data was too weak to assess the exact incidence of ON in IBD. Corticosteroid therapy, especially in high dose regimens, is likely the most important etiological factor. No evidence supporting other physiopathological hypothesis, such as total parenteral nutrition, osteoporosis, or coagulation disorders, was found. Finally, the multifocal form of ON appears particularly common in IBD, with some patients presenting multiple lesions of the hip, shoulder, knee and talus. CONCLUSIONS: ON in IBD, which is frequently multifocal, appears to be a complication of corticosteroid therapy, especially when high doses are used. We recommend regular ON checkups for corticosteroid-treated IBD patients. [less ▲]

Detailed reference viewed: 13 (2 ULg)
Full Text
Peer Reviewed
See detailOsteonecrosis of the jaw and bisphosphonate treatment for osteoporosis.
Rizzoli, Rene; Burlet, Nansa; Cahall, David et al

in BONE (2008), 42(5), 841-7

A potential side effect associated with bisphosphonates, a class of drugs used in the treatment of osteoporosis, Paget's disease and metastatic bone disease, is osteonecrosis of the jaw (ONJ). The ... [more ▼]

A potential side effect associated with bisphosphonates, a class of drugs used in the treatment of osteoporosis, Paget's disease and metastatic bone disease, is osteonecrosis of the jaw (ONJ). The incidence of ONJ in the general population is unknown; this rare condition also may occur in patients not receiving bisphosphonates. Case reports have discussed ONJ development in patients with multiple myeloma or metastatic breast cancer receiving bisphosphonates as palliation for bone metastases. These patients are also receiving chemotherapeutic agents that might impair the immune system and affect angiogenesis. The incidence or prevalence of ONJ in patients taking bisphosphonates for osteoporosis seems to be very rare. No causative relationship has been unequivocally demonstrated between ONJ and bisphosphonate therapy. A majority of ONJ occurs after tooth extraction. Furthermore, the underlying risk of developing ONJ may be increased in osteoporotic patients by comorbid diseases. Treatment for ONJ is generally conservative. [less ▲]

Detailed reference viewed: 30 (2 ULg)
Full Text
Peer Reviewed
See detailOsteonecrosis of the jaw in a male osteoporotic patient treated with denosumab
NEUPREZ, Audrey ULg; Coste, S; Rompen, Eric ULg et al

in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2014), 25

Osteonecrosis of the jaw (ONJ) is a clinical condition associated with long-term exposure to inhibitors of bone resorption, mainly bisphosphonates. Denosumab (DMab) is a human monoclonal antibody of the ... [more ▼]

Osteonecrosis of the jaw (ONJ) is a clinical condition associated with long-term exposure to inhibitors of bone resorption, mainly bisphosphonates. Denosumab (DMab) is a human monoclonal antibody of the receptor activator of nuclear factor kappa-B ligand. It prevents osteoclast-mediated bone resorption and is widely prescribed for the management of postmenopausal osteoporosis. Whereas ONJ has already been reported in women treated with DMab, we report for the first time the development of ONJ, following tooth extraction, in a male patient treated for idiopathic osteoporosis with DMab. Due to the constant increase in DMab prescription, for the management of osteoporosis, in both genders, physicians should be made aware of this potential risk. [less ▲]

Detailed reference viewed: 46 (14 ULg)
See detailOsteoporose : van bestrijding tot behandeling
Reginster, Jean-Yves ULg; Franchimont, P

in Medical Trends (1988), 7

Detailed reference viewed: 9 (1 ULg)
Full Text
Peer Reviewed
See detailOsteoporose bij de bejaarde
Reginster, Jean-Yves ULg; Taquet, AN; Fraikin, G

in Medi-Sfeer (2000), 103

Detailed reference viewed: 10 (1 ULg)
Full Text
Peer Reviewed
See detailL’ostéoporose chez la personne âgée
Reginster, Jean-Yves ULg; Taquet, AN; Fraikin, G

in Medi-Sphere (1999), 103

Detailed reference viewed: 13 (5 ULg)
Full Text
Peer Reviewed
See detailL'ostéoporose d'involution chez la femme
Reginster, Jean-Yves ULg; Devogelaer, J. P.; Kaufman, J. M. et al

in Revue Médicale de Liège (1999), 54(4), 335-40

Postmenopausal osteoporosis is now considered a major public health problem in aging women, due to the burden related to the consequent fractures. Over recent years, several pharmacological approaches ... [more ▼]

Postmenopausal osteoporosis is now considered a major public health problem in aging women, due to the burden related to the consequent fractures. Over recent years, several pharmacological approaches were developed for the prevention and treatment of osteoporosis. Besides regular physical exercise and calcium rich diet, calcium supplementation can be suggested to both genders, after seventy years as well as systematic vitamin D supplementation in order to cope with the frequent lack observed in our country. Hormone replacement therapy is the first choice in prevention of postmenopausal osteoporosis. Based on a careful evaluation of the needs of a postmenopausal woman as well as on the risk/benefit ratio derived from her individual risk factors, selective estrogen receptor modulators (raloxifene) or second generation bisphosphonates (alendronate) can be considered as alternative to estrogens. Due to its prohibitive cost, nasal calcitonin should be only considered for very specific cases. In osteoporosis confirmed by bone densitometry or by occurrence of fractures, bisphosphonate (alendronate) reduces subsequent fracture rate. Fluoride salts can, in some cases, improve spinal symptomatic osteoporosis. The use of etidronate, a molecule from the past, should be avoided as much as possible and, at any rate, strictly restricted to its legal indication including women with several vertebral crush fractures and severely decreased bone mineral density. [less ▲]

Detailed reference viewed: 45 (3 ULg)
Full Text
Peer Reviewed
See detailL’ostéoporose en questions : plus dure sera la chute
Reginster, Jean-Yves ULg

in Stethoscopie Magazine (1996), 63

Detailed reference viewed: 5 (1 ULg)